Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation ...

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of ...

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...

GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...

London: GSK plc has received approval from the US Food and Drug Administration (FDA) for Nucala (mepolizumab) as an add-on ...

Mepolizumab added to triple therapy improves exacerbation outcomes in moderate to severe COPD and is effective to 2 years of ...

The U.S. Food and Drug Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients ...

UK pharma major GSK (LSE: GSK) yesterday announced that the US Food and Drug Administration (FDA) has approved Nucala ...

The FDA approved mepolizumab (Nucala) for adults with inadequately controlled chronic obstructive pulmonary disease (COPD), ...

The Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD ...